natgillin/translations-raw huggingface dataset:
Dental post consisting of fibre-reinforced material with substantially uniformly directed fibers (8) and mountable in a tooth root canal for fixing a dental prosthetic structure on a tooth stump, wherein said post comprises a tapered portion extending over at least one third of its total length towards its proximal and (4), characterized in that at least one groove (5, 6, 7) is provided on the circumferential surface of said tapered portion extending in the length direction of said post with an inclined course with respect to the longitudinal axis of said post over part of the circumference or at most twice around the circumference of said tapered portion. 
Zubni potporanj koji se sastoji od vlaknima ojačanog materijala čija, su vlakna uglavnom jednolično usmjerena (8) i može se ugraditi u kanal korijena zuba radi učvršćivanja strukture zubne proteze na batrljku zuba, gdje navedeni potporanj sadrži suženi dio koji se pruža najmanje jednom trećinom njegove ukupne duljine prema njegovom prednjem kraju (4), naznačen time što se najmanje jedan utor (5, 6, 7), načinjen na obodnoj površini navedenog suženog dijela, pruža uzduž navedenog potpornja, s nagibom u odnosu na uzdužnu os navedenog potpornja po dijelu opsega ili najviše dvaput okolo opsega navedenog suženog dijela.
The reusable shipping container (C) of claim 11 wherein each of said plurality of sidewalls is detachably connected to the base (10). 
Transportni spremnik (C) za višekratnu upotrebu iz zahtjeva 11, naznačen time da je navedeni veći broj bočnih stjenki odvojivo spojen na postolje (10).
A combination as claimed in claim 1 in the form of a pharmaceutical composition comprising bortezomib and compound No. 
Kombinacija prema zahtjevu 1, naznačena time, da je u obliku farmaceutskog pripravka koji sadrži bortezomib i spoj br.
is C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, wherein R1 and the hydroxyl group on the ring are attached to the same carbon atom; 
je C1-6alkil, koji nije supstituiran ili je supstituiran s 1-6 fluora, gdje su R1 i hidroksilna skupina na prstenu vezani za isti atom ugljika. ili njegova farmaceutski prihvatljiva sol.
The compound of Claim 6 wherein R1 is selected from the group consisting of: methyl, ethyl, 
Spoj prema zahtjevu 6 gdje je R1 izabran iz grupe koja obuhvaća: metil, etil,
Use of a compound of any of claims 1-11 for the manufacture of a medicament for the treatment or prevention of a psychotic disorder. 
Uporaba spoja prema bilo kojem od zahtjeva 1-11 za proizvodnju lijeka za liječenje ili prevenciju psihotičnog poremećaja.
A compound according to any of claims 1-11 for use in treating schizophrenia, treating bipolar disorder, treating Alzheimer's disease, enhancing cognition or treating anxiety in a mammalian patient in need thereof. 
Spoj prema bilo kojem od zahtjeva 1-11 za uporabu u liječenju shizofrenije, liječenju bipolarnog poremećaja, liječenju Alzheimerove bolesti, poboljšanje kognitivnih sposobnosti ili liječenje anksioznosti u bolesnika sisavca kojemu je to potrebno.
4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and acid additions salts thereof for use in the treatment of ADHD. 
-[2-(4-metilfenilsulfanil)fenil]piperidin [image] i njegove kisele adicijske soli za uporabu u liječenju ADHD-a.
The compound for use according to claim 1, which compound is the HBr addition salt. 
Spoj za uporabu prema zahtjevu 1, taj spoj je HBr adicijska sol.
The compound for use according to claim 3, which compound is characterised by an XRPD as depicted in figure 1. 
Spoj za uporabu prema zahtjevu 3, taj spoj je naznačen XRPD-om kako je prikazano na slici 1.
L is a bond or is selected from, and wherein each group is drawn with its left end attached to the benzimidazole and its right end attached to R1; 
L je veza ili se izabire između [image] i [image] gdje je svaka skupina prikazana s lijevim krajem spojenim za benzimidazol i desnim krajem spojenim s R1;
The composition of claim 17 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Smjesa prema zahtjevu 17 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji potiče razvoj odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense RNA, imikvimoda, ribavirina, inhibitora dehidrogenaze inozin 5’-monofosfata, amantadina, i rimantadina.
The compound for use according to claim 22 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 22 koja dalje obuhvaća primjenu jednog ili dva dodatna spoja s anti-HCV aktivnošću prije, nakon ili istodobno sa spojem iz zahtjeva 1, ili njegova farmaceutski prihvatljiva sol.
The compound for use according to claim 24 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. 
Spoj za uporabu prema zahtjevu 24 gdje se interferon izabire između interferona alfa 2B, pegiliranog interferona alfa, konsenzus interferoan, interferona alfa 2A, i limfoblastoidnog interferona tau.
The compound for use according to claim 23 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Spoj za uporabu prema zahtjevu 23 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji potiče razvoj odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense RNA, imikvimoda, ribavirina, inhibitora dehidrogenaze inozin 5’-monofosfata, amantadina, i rimantadina.
providing at least one salt of a C5― C28 fatty acid selected from the group comprising mono-alcohol primary alkanolamine salts, polyethyleneimine salts, and mixtures thereof; 
osiguravanja barem jedne soli C5 - C28 masne kiseline koja je odabrana iz skupine koja sadrži soli primarnog mono-alkohol alkanolamina, soli polietilenimina, te njihove smjese;
The process according to any one of claims 1 to 8, characterized in that said salt of a C5―C28 fatty acid is a salt of a fatty acid having an iodine number of less than 5 g I2/100 g of fatty acid salt. 
Postupak prema bilo kojem zahtjevu od 1 do 8, naznačen time da navedena sol C5 - C28 masne kiseline je sol masne kiseline koja ima jodni broj od manje od 5 g I2/100 g soli masne kiseline.
The process according to any one of claims 1 to 9, characterized in that said salt of a C5―C28 fatty acid is a salt of a linear fatty acid if said fatty acid is a C6―C9 fatty acid. 
Postupak prema bilo kojem zahtjevu od 1 do 9, naznačen time da navedena sol C5 - C28 masne kiseline je sol linearne masne kiseline ako je navedena masna kiselina C6 - C9 masna kiselina.
The process according to any one of claims 1 to 9, characterized in that said salt of a C5―C28 fatty acid is a blend of palmitic acid salt(s) and stearic acid salt(s), preferably in a weight ratio based on the fatty acids of pahnitic acid: stearic acid of 2:1 to 1:2. 
Postupak prema bilo kojem zahtjevu od 1 do 9, naznačen time da navedena sol C5 - C28 masne kiseline je mješavina soli palmitinske kiseline i soli stearinske kiseline, poželjno sa težinskim omjerom od 2:1 do 1:2 masnih kiselina palmitinska kiselina: stearinska kiselina.
The process according to any one of claims 1 to 12, characterized in that, if said salt of a C5―C28 fatty acid is a polyethyleneimine salt, said polyethyleneimine is linear, preferably having a molecular weight of from 140 to 700 g/mol, and more preferably of from 146 to 232 g/mol. 
Postupak prema bilo kojem zahtjevu od 1 do 12, naznačen time, da ako je navedena sol C5 - C28 masne kiseline sol polietilenimina, navedeni polietilenimin je linearan, te poželjno ima molekularnu težinu od 140 do 700 g/mol, te poželjnije od 146 do 232 g/mol.
The process according to any one of claims 1 to 12, characterized in that, if said salt of a C5―C28 fatty acid is a monoalcohol primary alkanolamine salt, said monoalcohol primary alkanolamine is selected from the group comprising ethanolamine, propanolamines, butanolamines, pentanolamines and mixtures thereof, and preferably is a 1-amino-2-propanol salt of a C5―C28 fatty acid. 
Postupak prema bilo kojem zahtjevu od 1 do 12, naznačen time, da ako je navedena sol C5 - C28 masne kiseline sol primarnog mono-alkohol alkanolamina, navedeni primarni monoalkohol alkanolamin je odabran iz skupine koja sadrži etanolamin, propanolamine, butanolamine, pentanolamine i njihove smjese, te je poželjno sol 1-amino-2-propanol C5 - C28 masne kiseline.
%, based on the dry weight of said calcium carbonate-containing material, of said salt(s) of C5―C28 fatty acid(s). 
%, bazirano na težini suhe tvari navedenog materijala koji sadrži kalcijev karbonat, navedene(ih) soli C5 - C28 masne kiseline odnosno masnih kiselina.
The process according to any one of claims 1 to 15, characterized in that said calcium carbonate-containing material is treated with a total of 0.2 to 5 mg of said salt(s) of C5―C28 fatty acid(s) per m2 of calcium carbonate-containing material, and preferably with 0.5 to 2 mg of said salt(s) of C5― C28 fatty acid(s) per m2 of calcium carbonate-containing material. 
Postupak prema bilo kojem zahtjevu od 1 do 15, naznačen time da je navedeni materijal koji sadrži kalcijev karbonat obrađen sa ukupno od 0.2 do 5 mg navedene(ih) soli C5 - C28 masne kiseline odnosno masnih kiselina po m2 materijala koji sadrži kalcijev karbonat, te poželjno sa od 0.5 do 2 mg navedene(ih) soli C5 - C28 masne kiseline odnosno masnih kiselina po m2 materijala koji sadrži kalcijev karbonat.
Surface-treated calcium carbonate material according to claim 19, characterized in that it comprises 97 to 99 % by weight of a calcium carbonate material, 0.1 to 3 % by weight of monoalcohol primary monoalkanol amine and/or polyethyleneimine salt(s) of C5―C28 fatty acid(s) and 0 to 1.5 % by weight of calcium and/or magnesium salt(s) of C5―C28 fatty acid(s). 
Materijal od površinski obrađenog kalcijevog karbonata prema zahtjevu 19, naznačen time da sadrži od 97 do 99 % težinski kalcij karbonatnog materijala, od 0.1 do 3 % težinski primarnog monoalkohol monoalkanolamina i/ili soli polietilenimina C5 - C28 masne kiseline ili masnih kiselina i od 0 do 1.5 % težinski kalcijeve(ih) i/ili magnezijeve(ih) soli C5 - C28 masne kiseline odnosno masnih kiselina.
A compound represented by the following structural formula: or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein: ring A is an aryl or a heteroaryl, wherein the aryl or the heteroaryl are optionally further substituted with one or more substituents in addition to R3; 
Spoj prikazan slijedećom strukturnom formulom: [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu je prsten A aril ili heteroaril, pri čemu su aril ili heteroaril opcijskijoš supstituirani sa jednim ili više supstituenata pored R3;
The compound of Claim 1, wherein R5 is represented by the following formula: wherein: 
Spoj prema zahtjevu 1, pri čemu je R5prikazan slijedećom formulom:
The compound of Claim 1, wherein R5 is represented by the following structural formula: wherein: 
Spoj prema zahtjevu 1, pri čemu je R5prikazan slijedećom strukturnom formulom:
X6, for each occurrence, is independently CH, CR9, N, N(O), N+(R17), provided that at least three X6 groups are independently selected from CH and CR9; 
je u svakom slučaju nezavisno CH, CR9, N, N(O), N+(R17), pod uvjetom da su barem tri X6skupine nezavisno izabrane od CH i CR9;
X7, for each occurrence, is independently CH, CR9, N, N(O), N+(R17), provided that at least three X7 groups are independently selected from CH and CR9; 
je u svakom slučaju nezavisno CH, CR9, N, N(O), N+(R17), pod uvjetom da su barem tri X7skupine su nezavisno izabrane od CH i CR9;
The compound of Claim 1, wherein R5 is selected from the group consisting of: wherein: 
Spoj prema zahtjevu 1, pri čemu R5 je izabran iz skupine koju čine:
or two R9 groups taken together with the carbon atoms to which they are attached form a fused ring; and 
Ili dvije skupine R9uzete zajedno sa ugljikovim atomom za koji su vezane čine spojeni prsten; i
The compound of Claim 34, wherein the compound is represented by the following structural formula: or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein: 
Spoj prema zahtjevu 34, pri čemu je spoj prikazan slijedećom strukturnom formulom: [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu:
The compound of Claim 1, wherein the compound is represented by one of the following structural formulas: or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein: 
Spoj prema zahtjevu 1, pri čemu je spoj prikazan jednom od slijedećih strukturnih formula: [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu:
The compound of claim 2, selected from the group consisting of: 
Spoj prema zahtjevu 2, izabran iz skupine koju čine:
The compound of claim 19, wherein X4, is NR42 and X42 is CR44. 
Spoj prema zahtjevu 19, pri čemu X4 je NR42 i X42 je CR44.
The compound of claim 19, wherein R4, is selected from the group consisting of -H, lower alkyl, lower alkoxy, lower cycloalkyl, and lower cycloalkoxy. 
Spoj prema zahtjevu 19, pri čemu je R4 izabran iz skupine koju čine –H, niži alkil, niži alkoksi, niži cikloalkil i niži cikloalkoksi.
The compound of claim 19, wherein R41 is selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu je R41 izabran iz skupine koju čine –H, metil, etil, propil, izopropil, ciklopropil, metoksi, etoksi, propoksi i ciklopropoksi.
The compound of claim 19, wherein X41 is NR42, and R42 is selected from the group consisting of -H, a lower alkyl, a lower cycloalkyl, -C(O)N(R27)2, and -C(O)OH, wherein each R27 is independently -H or a lower alkyl. 
Spoj prema zahtjevu 19, pri čemu X41 je NR42 i R42 je izabran iz skupine koju čine –H, niži alkil, niži cikloalkil, -C(O)N(R27)2, i -C(O)OH, pri čemu svaki R27 je nezavisno –H ili niži alkil.
The compound of claim 19, wherein R43 and R44 are, independently, selected from the group consisting of-H, methyl, ethyl, propyl, isopropyl, and cyclopropyl. 
Spoj prema zahtjevu 19, pri čemu su R43 i R44 nezavisno izabrani iz skupine koju čine –H, metil, etil, propil, izopropil i ciklopropil.
The compound of claim 19, wherein X42 is CR44; Y40 is CR43; and R43 and R44 together with the carbon atoms to which they are attached form a cycloalkenyl, an aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 19, pri čemu X42je CR44; Y40 je CR43 i R43 i R44 zajedno sa ugljikovim atomima za koje su vezani čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
The compound of claim 27, wherein R43 and R44 together with the carbon atoms to which they are attached form a C5-C8 cycloalkenyl or a C5-C8 aryl. 
Spoj prema zahtjevu 27, pri čemu R43 i R44 zajedno sa ugljikovim atomima za koje su vezani čine C5-C8 cikloalkenil ili C5-C8 aril.
The compound of claim 27, wherein R45 is selected from the group consisting of -H, -OH, -SH, -NH2, a lower alkoxy, and a lower alkyl amino. 
Spoj prema zahtjevu 27, pri čemu R45 je izabran iz skupine koju čine –H, -OH, -SH, -NH2, niži alkoksi i niži alkil amino.
The compound of Claim 29, wherein R45 is selected from the group consisting of-H, -OH, methoxy and ethoxy. 
Spoj prema zahtjevu 29, pri čemu je R45 izabran iz skupine koju čine –H, OH, metoksi i etoksi.
The compound of claim 19, wherein said compound is selected from the group consisting of: 
Spoj prema zahtjevu 19, pri čemu je navedeni spoj izabran iz skupine koju čine:
The compound of Claim 19, wherein the compound is represented by the following structural formula: or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein Z1 is -OH or-SH. 
Spoj prema zahtjevu 19, pri čemu je spoj prikazan slijedećom strukturnom formulom: [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat iliklatrat, pri čemu Z1 je –OH ili –SH.
The compound of claim 34, wherein X42 is CR44, and R43 and R44 are, independently, selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, and cyclopropyl. 
Spoj prema zahtjevu 34, pri čemu X42 je CR44 i R43 i R44 su nezavisno izabrani iz skupine koju čine –H, metil, etil, propil, izopropil i ciklopropil.
The compound of claim 34, wherein X42 is CR44, and R43 and R44, taken together with the carbon atoms to which they are attached, form a cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 34, pri čemu X42 je CR44 i R43 i R44, uzeti zajedno sa ugljikovim atomima za koje su vezani, čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
The compound of claim 36, wherein R43 and R44, taken together with the carbon atoms to which they are attached, form a C5-C8 cycloalkenyl or a C5-C8 aryl. 
Spoj prema zahtjevu 36, pri čemu R43 i R44, uzeti zajedno sa ugljikovim atomima za koje su vezani čine C5-C8 cikloalkenil ili C5-C8 aril.
The compound of claim 34, wherein X42 is CR44. 
Spoj prema zahtjevu 34, pri čemu X42 je CR44.
The compound of claim 1, wherein X is N. 
Spoj prema zahtjevu 1, pri čemu X je N.
is selected from the group consisting of -H, methyl, ethyl, isopropyl, and cyclopropyl; 
je izabran iz skupine koju čine –H, metil, etil, izopropil i ciklopropil;
and R54 are each, independently, -H, methyl, ethyl, or isopropyl; or R53 and R54 taken together with the carbon atoms to which they are attached form a phenyl, cyclohexenyl, or cyclooctenyl ring; and 
i R54 su svaki nezavisno –H, metil, etil ili izopropil; ili R53 i R54 uzeti zajedno sa ugljikovim atomima za koje su vezani čine fenil, cikloheksenil ili ciklooktenil prsten; i
The compound of claim 19, wherein said compound is: 
Spoj prema zahtjevu 19, pri čemu je navedeni spoj:
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1,3-dimethyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
Spoj prema zahtjevu 19, pri čemu je navedeni spoj 3-(2,4-dihidroksi-5-izopropil-fenil)-4-(1,3-dimetil-indol-5-il)-5-hidroksi-[1,2,4]triazol ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2.4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
Spoj prema zahtjevu 19, pri čemu je navedeni spoj 3-(2,4-dihidroksi-5-izopropil-fenil)-4-(1-metil-indol-5-il)-5-hidroksi-[1,2,4]-triazol ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-isopropyl-indol-4-yl)-5-hydroxy-[1,2,4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
Spoj prema zahtjevu 19, pri čemu navedeni spoj je 3-(2,4-dihidroksi-5-izopropil-fenil)-4-(1-izopropil-indol-4-il)-5-hidroksi-[1,2,4]-triazol ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
The compound of claim 19, wherein said compound is selected from the group consisting of 
Spoj prema zahtjevu 19, pri čemu navedeni spoj je izabran iz skupine koju čine
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropylphenyl)-4-(N-methyl-indol-5-yl)-5-mercapto-[1,2,4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
Spoj prema zahtjevu 19, pri čemu je navedeni spoj3-(2,4-dihidroksi-5-izopropilfenil)-4-(N-metil-indol-5-il)-5-merkapto-[1,2,4]triazol, ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
treating or preventing a proliferative disorder in a mammal; 
liječenje ili sprječavanje proliferativnog poremećaja kod sisavaca;
A pharmaceutical composition as claimed in Claim 50, wherein the composition further comprises one or more other prophylactic or therapeutic agents. 
Farmaceutski sastav prema zahtjevu 50, pri čemu sastav dalje obuhvaća jedan ili više profilaktičkih terapeutskih sredstava.
or two R9 groups taken together with the carbon atoms to which they are attached form a fused ring; 
Ili dvije skupine R9uzete zajedno sa ugljikovim atomom za koji su vezane čine spojeni prsten; i
The pyrazine derivative according to claim 6 or 7, wherein the neuraminidase inhibitor is oseltamivir or zanamivir. 
Derivat pirazina u skladu sa zahtjevom 6 ili 7, naznačen time, da je neuraminidaza inhibitor oseltamivir ili zanamivir.
The pyrazine derivative according to claim 6 or 7, wherein the neuraminidase inhibitor is oseltamivir. 
Derivat pirazina u skladu sa zahtjevom 6 ili 7, naznačen time, da je neuraminidaza inhibitor oseltamivir.
The pyrazine derivative according to claim 6 or 7, wherein the neuraminidase inhibitor is zanamivir. 
Derivat pirazina u skladu sa zahtjevom 6 ili 7, naznačen time, da je neuraminidaza inhibitor zanamivir.
A kit for the parenteral administration of drugs with an intravenous approach which comprises at least: a container holding a fluid for parenteral infusion; 
Komplet za parenteralno davanje lijekova intravenoznim putem koji sadrži barem: spremnik za držanje fluida za intravenoznu infuziju izrađen od složivog materijala;
The kit according to claim 9 characterised in that said means for transferring the pharmaceutical composition from the dosage unit (b) to the container (a) is a connector with at least two spikes. 
Komplet prema patentnom zahtjevu 5, naznačen time, da navedeno sredstvo za prijenos farmaceutskog sastava iz jedinice doziranja (b) u spremnik (a) jest spojni komad s barem dva probojna šiljka.
A composition comprising a compound of claim 51, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
Sastav, naznačen time da sadrži spoj prema zahtjevu 51 ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljivi nosač.
A method of inhibiting the HGF/c-Met kinase signaling pathway in a cell ex vivo comprising contacting said cell with a compound of any one of claims 1 to 51, or pharmaceutically acceptable salt thereof. 
Metoda inhibiranja signalnog puta HGF/c-Met kinaze u stanici ex vivo, naznačena time da uključuje dovođenje navedene stanice u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
The compound, or pharmaceutically acceptable salt thereof, of claim 62 for use in treating a disease a wherein said disease is cancer, atherosclerosis, lung fibrosis, renal fibrosis and regeneration, liver disease, allergic disorder, inflammatory disease, autoimmune disorder, cerebrovascular disease, cardiovascular disease, or condition associated with organ transplantation. 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 62, naznačeni time da se upotrebljavaju u liječenju bolesti pri čemu je navedena bolest rak, ateroskleroza, plućna fibroza, renalna fibroza i regeneracija, bolest jetre, alergijski poremećaj, upalna bolest, autoimuni poremećaj, cerebrovaskularna bolest, kardiovaskularna bolest ili stanje povezano sa transplantacijom organa.